Annexon (NASDAQ:ANNX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.
Annexon (NASDAQ:ANNX – Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, analysts expect Annexon to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Annexon Stock Down 3.6 %
ANNX opened at $2.40 on Friday. The firm has a market cap of $263.30 million, a P/E ratio of -2.29 and a beta of 1.14. Annexon has a 52 week low of $2.30 and a 52 week high of $8.40. The business’s fifty day simple moving average is $3.25 and its 200 day simple moving average is $5.10.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Annexon
Annexon Company Profile
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Annexon
- How to Buy Cheap Stocks Step by Step
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- 3 Best Fintech Stocks for a Portfolio Boost
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Are Penny Stocks a Good Fit for Your Portfolio?
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.